Background Whether or not second-generation antipsychotics (SGAs) represent an
advantage over first-generation antipsychotics (FGAs) in the treatment of schizophrenia is …

Background Long-acting injectable risperidone, a second-generation antipsychotic agent,
may improve adherence to treatment and outcomes in schizophrenia, but it has not been …

Background The question of which antipsychotic drug should be preferred for the treatment
of schizophrenia is controversial, and conventional pairwise meta-analyses cannot provide …

Objective: Antipsychotic drug efficacy may have decreased over recent decades. The
authors present a meta-analysis of all placebo-controlled trials in patients with acute …

Objective: Whether there are differences in efficacy among second-generation
antipsychotics in the treatment of schizophrenia is a matter of heated debate. The authors …